All research
Tirzepatide 2026-06-13 PubMed

Computational framework links Liquorice Root, Mulberry Leaf, and other herbs to GLP-1 RA adverse event patterns

Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity.

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for obesity management and type 2 diabetes, yet their widespread use highlights persistent concerns regarding adverse events (AEs). Current clinical understanding often lacks comprehensive insights into potential interactions, particularly with herbal supplements. This gap necessitates advanced methods to identify and characterize AE patterns and explore novel associations, such as those involving herbal compounds, which could impact patient safety and therapeutic outcomes. Understanding these interactions is crucial for optimizing GLP-1 RA therapy.

Study Design

Researchers conducted a cross-sectional analysis of 142,705 GLP-1 RA AE reports from the FDA Adverse Event Reporting System (FAERS) spanning 2015-2025, with 4,090 reports specifically for obesity indications. Clinical characteristics like outcomes, reporting frequency, demographics, and time-to-onset were analyzed. Signal detection utilized disproportionality metrics and Bayesian approaches. Herb-compound-target-AE networks were constructed using HERB 2.0 and the Comparative Toxicogenomics Database, incorporating drug-likeness and pharmacokinetic filtering. Graph convolutional networks (GCN) were then applied to model herb-AE associations, followed by literature-based contextual evaluation.

Results

Gastrointestinal events predominated among the GLP-1 RA AE reports, with 76% involving female patients and onset clustering within 0-30 days. Semaglutide exhibited a distinct onset distribution, including a higher proportion of late-onset cases (≥ 360 days). Strong signals were detected for biliary, pancreatic, renal, and coagulation events. Specifically, semaglutide-associated pairs showed reporting odds ratios > 10 for these serious AEs. Conversely, tirzepatide demonstrated negative log-transformed reporting odds ratios for several gastrointestinal events, suggesting a potentially different AE profile. Network analysis and GCN modeling prioritized several established medicinal herbs as top candidates associated with AE patterns: > Liquorice Root, Mulberry Leaf, Dahurian Angelica Root, Danshen Root, and Ginkgo Leaf were identified after degree debiasing and exclusion of non-herbal database entries. The GCN achieved an area under the receiver operating characteristic curve (AUC/AR) of 0.85, indicating good predictive performance.

Key Findings

  • 142,705 GLP-1 RA adverse event reports analyzed, with 4,090 specific to obesity indications.
  • Gastrointestinal events were predominant, with 76% of reports from female patients and onset within 0-30 days.
  • Semaglutide showed a higher proportion of late-onset AEs (≥ 360 days).
  • Strong AE signals detected for biliary, pancreatic, renal, and coagulation events, with semaglutide pairs showing reporting odds ratios > 10.
  • Liquorice Root, Mulberry Leaf, Dahurian Angelica Root, Danshen Root, and Ginkgo Leaf were prioritized as top herb candidates associated with AE patterns.

Why It Matters

This study provides a critical, data-driven perspective on GLP-1 RA safety, particularly highlighting potential interactions with common herbal supplements. Patients using GLP-1 RAs for obesity should exercise caution with identified herbs like Liquorice Root and Mulberry Leaf, and clinicians should consider these potential interactions when managing AEs. The computational framework offers a proactive tool for pharmacovigilance, potentially informing future clinical guidelines and drug development by identifying high-risk herb-drug combinations before they manifest widely in the real world. This approach could lead to more personalized safety protocols, enhancing the overall risk-benefit profile of GLP-1 RA therapies.


glp-1-ra obesity adverse-events pharmacovigilance herbal-medicine computational-biology
Source: pubmed:42286047 · Ingested 2026-06-13 · Digest: gemini-2.5-flash